ABSTRACT
Objective To evaluate the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) in treatment of patients with liver cancer.Methods Totally 20 patients with liver cancer undergoing DEB-TACE treatment were enrolled.Clinical efficacy included complete response (CR),partial response (PR),stable disease (SD) and progressive disease (PD).The overall response rate (ORR) was defined as proportion of patients achieved CR and PR.Results After treatment of DEB-TACE,the ORR,CR,PR,SD,and PD of patients were 80.00％ (16/20),40.00％ (8/20),40.00％ (8/20),15.00％ (3/20),and 5.00％ (1/20),respectively;while for single tumor nodule,the ORR,CR,PR,SD,and PD were 81.58％ (31/32),50.00 (19/38)％,31.58％ (12/38),15.79％ (6/38),and 2.63％ (1/38),respectively.After the treatment of DEB-TACE,the relapse free survival rate in half year was 85.00％,and the overall survival rate was 95.00％.The adverse events of patients were mild pain,fever,nausea and vomiting.Conclusion CalliSpheres(R) DEB-TACE is an effective and well tolerated treatment in liver cancer patients.